New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia

Published:2018-10-17 Issue:11 Volume:38 Page:1143-1154
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Click Zach R.¹^ORCID,Seddon Amanda N.¹²,Bae Young R.³,Fisher Justin D.⁴,Ogunniyi Adebayo⁵

Affiliation:

1. Rush University Medical Center; Chicago Illinois

2. Midwestern University Chicago College of Pharmacy; Downers Grove Illinois

3. Northshore University Health System; Evanston Illinois

4. Northwestern Memorial Hospital; Chicago Illinois

5. Memorial Sloan Kettering; New York New York

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/phar.2180/fullpdf

Reference49 articles.

1. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia;Patel;N Engl J Med,2012

2. Howlader N Noone A Krapcho M SEER cancer stat facts: acute myeloid leukemia https://seer.cancer.gov/statfacts/html/amyl.html

3. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Acute myeloid leukemia version 1. 2018 https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf

4. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B;Rai;Blood,1981

5. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment;Grafone;Oncol Rev,2012

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia;British Journal of Haematology;2023-05-14

2. miRNA-222-3p enhances the proliferation and suppresses the apoptosis of acute myeloid leukemia cells by targeting Axin2 and modulating the Wnt/β-catenin pathway;Biochemical and Biophysical Research Communications;2022-09

3. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis;Nature Cancer;2021-11

4. Investigation of pathogenesis and therapeutic targets of acute myeloid leukemia based on untargeted plasma metabolomics and network pharmacology approach;Journal of Pharmaceutical and Biomedical Analysis;2021-02

5. Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine;Nature Communications;2020-08-26